A composition for use in protecting the breast tissue and significantly lowering the high risk for breast cancer development in women includes Ganoderma Lucidum, Quercetine, Embilica officinalis, Indole 3 carbinol, Camellia sinensis, Allium sativum, Iodine, and Selenium.

The Basic Mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1,000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Soy extract containing Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, and Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1 mg-2,000 mg. Mix 1 is effective in repressing the transcription of ApoE gene in fibroblast cells. The formulations counters specific pathology markers, alleviates markers associated with increased risk of degenerative problems (i.e. Alzheimer's disease).

The Basic Mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1,000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Soy extract containing Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, and Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1 mg-2,000 mg. Mix 1 is effective in repressing the transcription of ApoE gene in fibroblast cells. The formulations counters specific pathology markers, alleviates markers associated with increased risk of degenerative problems (i.e. Alzheimer's disease).

The present invention relates generally to a method of treating infectious conjunctivitis by administering to an infected eye of a subject a composition comprising povidone-iodine and an excipient that reduces the ocular toxicity of the composition, wherein the composition does not include a steroidal anti-inflammatory drug or a non-steroidal anti-inflammatory drug.

Ophthalmic compositions for administration to an eye including a mixture of an antiseptic and an anesthetic in therapeutically effective amounts are disclosed. The compositions are both anesthetic and antiseptic, and can be used in various ophthalmic procedures.

Ophthalmic compositions for administration to an eye including a mixture of an antiseptic and an anesthetic in therapeutically effective amounts are disclosed. The compositions are both anesthetic and antiseptic, and can be used in various ophthalmic procedures.

A bactericidal composition comprising a carboxy group-containing cellulose ester or carboxy group-containing cellulose ether, a bactericide, alcohol, and water. Some embodiments further comprise a plasticizer. The compositions described herein may be used to disinfect the surface of skin in preparation for surgical procedures.

A bactericidal composition comprising a carboxy group-containing cellulose ester or carboxy group-containing cellulose ether, a bactericide, alcohol, and water. Some embodiments further comprise a plasticizer. The compositions described herein may be used to disinfect the surface of skin in preparation for surgical procedures.

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.